Breaking News Instant updates and real-time market news.

ADMS

Adamas Pharmaceuticals

$6.64

-0.4 (-5.68%)

, ACOR

Acorda Therapeutics

$2.99

-0.01 (-0.33%)

06:27
09/30/19
09/30
06:27
09/30/19
06:27

Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill

BofA/Merrill analyst Tazeen Ahmad downgraded Adamas Pharmaceuticals (ADMS) to Underperform and lowered his price target to $5 from $9. The analyst cites indications of a "limited" uptake of ADS-5102 by doctors in multiple sclerosis, adding that the drug's phase 2 trial data have demonstrated comparable response and more safety concerns than the current standard-of-care with Ampyra made by Acorda Therapeutics (ACOR). Ahmad is also increasing his discontinuation rate assumption for '5102 to 30% and lowers his risk-adjusted peak sales estimate to $324M from $365M.

ADMS

Adamas Pharmaceuticals

$6.64

-0.4 (-5.68%)

ACOR

Acorda Therapeutics

$2.99

-0.01 (-0.33%)

  • 02

    Oct

ADMS Adamas Pharmaceuticals
$6.64

-0.4 (-5.68%)

09/09/19
CANT
09/09/19
INITIATION
Target $8
CANT
Neutral
Adamas Pharmaceuticals initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan initiated Adamas Pharmaceuticals with a Neutral and $8 price target.
09/09/19
CANT
09/09/19
INITIATION
Target $8
CANT
Neutral
Adamas Pharmaceuticals initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan started Adamas Pharmaceuticals with a Neutral rating and $8 price target. The lack of conviction in Gocovri sales growth is priced into the stock, but positive sales trends in the next 6-12 months are "needed to facilitate a turn in this battleground story," Duncan tells investors in a research note.
09/09/19
09/09/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CrossFirst Bancshares (CFB) initiated with an Outperform at Keefe Bruyette and a Market Perform at Raymond James. 2. Murphy Oil (MUR) initiated with an Overweight at KeyBanc. 3. resTORbio (TORC) initiated with an Overweight at Cantor Fitzgerald while Adamas Pharmaceuticals (ADMS) was initiated with a Neutral. 4. Altice USA (ATUS) initiated with a Buy at Benchmark. 5. Perficient (PRFT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/19
BOFA
09/30/19
DOWNGRADE
BOFA
Underperform
Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill
ACOR Acorda Therapeutics
$2.99

-0.01 (-0.33%)

05/22/19
WEDB
05/22/19
INITIATION
Target $12
WEDB
Neutral
Acorda Therapeutics initiated with a Neutral at Wedbush
Wedbush analyst Laura Chico started Acorda Therapeutics with a Neutral rating and $12 price target.
05/23/19
05/23/19
INITIATION
Target $12

Neutral
Acorda Therapeutics initiated with a Neutral at Wedbush
As previously reported, Wedbush analyst Laura Chico started Acorda Therapeutics with a Neutral rating and $12 price target. The analyst notes that the loss of exclusivity for the company's flagship Ampyra product has led to Inbrija - its inhaled levodopa product for the treatment of OFF episodes in Parkinson's disease - to the forefront of its lineup. Chico states that while her recent survey suggests that physicians will continue to increase their Inbrija utilization, it is unclear how many patients may be "appropriate candidates for the drug," and with only 2 months on the market, additional feedback is needed on its potential expected demand.
08/02/19
CANT
08/02/19
NO CHANGE
Target $12
CANT
Neutral
Acorda Therapeutics price target lowered to $12 from $20 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan lowered his price target for Acorda Therapeutics to $12 from $20 following the company's Q2 results and reiterates a Neutral rating on the shares. The analyst believes Acorda's "fate" and ability to become cash flow positive as being in the hands of Inbrija, and he remains "cautiously optimistic." However, citing the potential for several quarters being needed for revenue to ramp to a substantive level, he reduced his target based on lower multiples.
08/14/19
HCWC
08/14/19
DOWNGRADE
Target $6
HCWC
Neutral
Acorda Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju downgraded Acorda Therapeutics to Neutral from Buy and lowered his price target for the shares to $6 from $31. The "anemic" sales trajectory for Inbrija is concerning, particularly in light of the $323.8M in convertible notes maturing June 15, 2021, Selvaraju tells investors in a research note. Inbrija sales are not growing fast enough to pick up the slack Amprya is leaving behind, says the analyst. Further, he believes Acorda is "running out of runway" because of the impending maturity of the 2021 convertible notes. As such, Selvaraju feels the stock's risk profile is not currently appealing.

TODAY'S FREE FLY STORIES

CVX

Chevron

$119.17

0.37 (0.31%)

13:39
11/22/19
11/22
13:39
11/22/19
13:39
Periodicals
Chevron plans sweeping cost-cutting, streamlining efforts, Reuters reports »

Chevon's CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$49.21

0.24 (0.49%)

, ARZGY

Generali

$0.00

(0.00%)

13:33
11/22/19
11/22
13:33
11/22/19
13:33
Periodicals
Generali nearing over $3B bid for MetLife European assets, Bloomberg reports »

Assicurazioni Generali…

MET

MetLife

$49.21

0.24 (0.49%)

ARZGY

Generali

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SONO

Sonos

$15.43

1.21 (8.51%)

13:25
11/22/19
11/22
13:25
11/22/19
13:25
Options
Sonos call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
11/22/19
11/22
13:17
11/22/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
11/22/19
11/22
13:16
11/22/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$22.59

(0.00%)

13:04
11/22/19
11/22
13:04
11/22/19
13:04
Hot Stocks
Baker Hughes reports U.S. rig count down 3 to 803 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOLD

Audentes Therapeutics

$28.17

0.05 (0.18%)

13:02
11/22/19
11/22
13:02
11/22/19
13:02
Recommendations
Audentes Therapeutics analyst commentary  »

Piper remains buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNL

Synalloy

$13.45

(0.00%)

13:01
11/22/19
11/22
13:01
11/22/19
13:01
Hot Stocks
Synalloy board of directors decides not to make annual dividend payment »

Synalloy Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$22.60

0.01 (0.04%)

13:01
11/22/19
11/22
13:01
11/22/19
13:01
Hot Stocks
Breaking Hot Stocks news story on Baker Hughes »

Baker Hughes reports U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$119.65

-0.23 (-0.19%)

12:53
11/22/19
11/22
12:53
11/22/19
12:53
Periodicals
Walmart's Jet.com to stop delivering fresh groceries, CNBC reports »

Walmart's Jet.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$30.99

-0.45 (-1.43%)

12:48
11/22/19
11/22
12:48
11/22/19
12:48
Recommendations
Skyline analyst commentary  »

SunTrust boosts Skyline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:47
11/22/19
11/22
12:47
11/22/19
12:47
Hot Stocks
Breaking Hot Stocks news story  »

Civista Bancshares…

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

12:46
11/22/19
11/22
12:46
11/22/19
12:46
Periodicals
Breaking Periodicals news story on We Company, SoftBank, SoftBank »

WeWork chairman lays out…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Z

Zillow

$41.03

1.22 (3.06%)

12:45
11/22/19
11/22
12:45
11/22/19
12:45
Options
Zillow call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
11/22/19
11/22
12:45
11/22/19
12:45
General news
Breaking General news story  »

Week of 11/22…

12:45
11/22/19
11/22
12:45
11/22/19
12:45
General news
Breaking General news story  »

Week of 11/22…

12:42
11/22/19
11/22
12:42
11/22/19
12:42
Hot Stocks
Breaking Hot Stocks news story  »

Civista Bancshares…

BIIB

Biogen

$294.17

5.51 (1.91%)

12:33
11/22/19
11/22
12:33
11/22/19
12:33
Periodicals
Breaking Periodicals news story on Biogen »

Biogen settles Tecfidera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

BIIB

Biogen

$293.68

5.02 (1.74%)

12:26
11/22/19
11/22
12:26
11/22/19
12:26
Hot Stocks
Breaking Hot Stocks news story on Biogen »

Biogen rallies 3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

FTCH

Farfetch

$9.73

0.335 (3.57%)

12:25
11/22/19
11/22
12:25
11/22/19
12:25
Options
Farfetch Limited call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$310.63

0.34 (0.11%)

12:18
11/22/19
11/22
12:18
11/22/19
12:18
General news
Ray Dalio says WSJ wrong, Bridgewater not betting market will fall »

Ray Dalio, Co-Chief…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$310.63

0.34 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/22/19
11/22
12:17
11/22/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/22/19
11/22
12:16
11/22/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$53.30

-0.425 (-0.79%)

12:15
11/22/19
11/22
12:15
11/22/19
12:15
Options
Dell Technologies put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 02

    Dec

  • 09

    Dec

  • 09

    Dec

12:15
11/22/19
11/22
12:15
11/22/19
12:15
General news
Treasury Action: the markets are mixed with no strong directional drivers »

Treasury Action: the…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.